These findings also support targeting of mTORC2, which is activated due to the inhibition of EGFR/mTORC1/S6K signaling [53], as another therapeutic strategy to overcome EGFR TKI resistance in NSCLC cells [72]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.